MEI Pharma, Inc. (MEIP)

[conix]

MEIP Investment Highlights:

*Four Clinical-Stage Programs; Multiple near-term Milestones in Oncology related areas

*Combination & Mono Therapies Targeting Multiple Pathways

*As of end of 1st Qtr. 2019, comapny has $93 million in Cash to achieve key Milestones across programs

*In Phase 3 Pivotal Trial for Acute Myeloid Leukemia w/ drug 'Pracinostat'(HDAC Inhibitor)

*In Phase 2 Accelerated Approval Trial with drug 'ME-401' for Follicular Lymphoma

*Early-Stage drug 'ME-344" targeting Breast Cancer

*Voruciclib(CDK Inhibitor) - B-Cell Malignancies and AML - Phase 1

*20,000 new U.S. Cases in 2018 for AML; HER2/breast Cancer - 200k new cases annually


Corporate Overveiw:

MEIP is a San Diego-based late-stage pharmaceutical company focused on building a leading oncology franchise. Itsportfolio of drug candidates contains four clinical-stage candidates, including one candidate in an ongoing Phase 3 global registration trial and another candidate that is entering a clinical study to support an accelerated approval marketing application with the U.S. Food and Drug administration.

Market Capitalization: $120 million
Current Price: $1.48
YTD H-L: $4.80 - $1.52
Symbol: MEIP

Website: www.meipharma.com